NDXP250103C22720000
- 0.00
- 0.000.00%
NASDAQ 100 Index Newsroom
Fed Meeting Minutes to Shed Light on Rate-Cut Path in 2025
Honeywell And NXP Expand Partnership To Accelerate Next-Gen Aviation Tech With AI-Driven Cockpit Displays, Enhanced Autonomy, And Operational Efficiency; Vertical Aerospace To Leverage New Solutions For EVTOL Aircraft
US Morning News Call | Nvidia CEO's Remarks Trigger Pre-Market Plunge in Quantum Stocks
The three major U.S. stock index futures all turned to decline amid rumors of tariffs from Trump affecting risk appetite | Highlights for tonight.
① It is reported that Trump is considering declaring a national economic emergency to introduce tariffs; ② NASDAQ 100 Index futures dropped over 0.5% in pre-market trading; ③ Meta ended its fact-checking program to extend an olive branch to Trump; ④ The Indonesian government warned that if Apple does not comply with local investment regulations, it may face "sanctions" in the worst-case scenario.
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Pre-Market Trading Key Points | Is Trump's tariff plan changing? The December "small non-farm" data will be announced soon.
The three major Equity Index futures in the USA all dropped, with Nasdaq futures down 0.6%, S&P 500 Index futures down 0.45%, and Dow futures down 0.29%.
Will the Federal Reserve's meeting minutes release tonight continue to signal a "hawkish" stance?
This meeting minutes focus on: the degree of divergence among Federal Reserve officials, the determination of the persistence of inflation and the weakness of the labor market, as well as discussions on the rise of neutral interest rates to a higher level. Additionally, the impact of Trump's policies and details related to balance sheet reduction are also worth noting.
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
MercadoLibre Analyst Ratings
This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Absci, AMD Announce Strategic Collaboration; AMD To Also Make $20M Investment In Absci, Structured As Private Investment In Public Equity
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Advanced Micro Devices Analyst Ratings
Demystifying Autodesk: Insights From 20 Analyst Reviews
Express News | Trump Considering National Economic Emergency
Biogen Analyst Ratings
Amgen Analyst Ratings
Dell Simplifies PC Lineup With Apple-Like Branding: XPS, Inspiron Brands Are Gone For Good
Top 3 Tech Stocks That May Rocket Higher This Quarter
December US Nonfarm Payrolls Preview | Economic Data May Boost Asset Volatility